Jupiter Neurosciences doses first patient in Parkinson’s Phase 2a study
Jupiter Neurosciences has dosed the first participant in RESET, its Phase 2a study of JOTROL for Parkinson’s disease. The randomized, placebo-controlled trial will assess safety, tolerability, pharmacokinetics and biomarkers. Separately, the company retained Tungsten Advisors to evaluate options including asset sales, licensing, partnerships and potential corporate transactions.
Why it matters
The first dose moves Jupiter’s lead program into patient testing, with clinical data to inform its further development. The strategic review could lead to a licensing deal, partnership, asset sale or other transaction, though the company said no transaction is assured.
Key facts
- 1Jupiter Neurosciences announced the first patient was dosed in the RESET Phase 2a trial of JOTROL in Parkinson’s disease. globenewswire.com
- 2RESET is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial. globenewswire.com
- 3The study is expected to enroll approximately 30 patients, assigned 1:1:1 to two JOTROL dose levels or placebo. globenewswire.com
- 4Study treatment will be given orally for 12 weeks. globenewswire.com
- 5Jupiter retained Tungsten Advisors to assess strategic alternatives for its development programs and other possible transactions. globenewswire.com
- 6The company said it cannot assure that the strategic process will produce a transaction. globenewswire.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.